Apex Biotechnology Corp. (TPE:1733)

Apex Biotechnology Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	484.48	532.69	382.05	331.71	555.33	786.95
Trading Asset Securities	76.63	66.1	61.87	65.83	69.72	36.01
Cash & Short-Term Investments	561.11	598.78	443.91	397.53	625.05	822.96
Cash Growth	20.21%	34.89%	11.67%	-36.40%	-24.05%	2.48%
Accounts Receivable	442.79	346.64	288.39	486.77	474.41	325.41
Other Receivables	12.75	8.08	5.72	10.12	13.97	17.28
Receivables	455.53	354.72	294.11	496.89	488.38	342.68
Inventory	526.84	662.49	747.71	739.25	628.59	504.54
Prepaid Expenses	22.57	24.78	18.51	19	11.06	13.47
Other Current Assets	1.82	2.29	2.4	1.81	6.78	0.83
Total Current Assets	1,568	1,643	1,507	1,654	1,760	1,684
Property, Plant & Equipment	661.42	695.81	720.59	766.08	794.12	827.81
Other Intangible Assets	35.35	39.6	44.22	69.14	106.48	128.92
Long-Term Deferred Tax Assets	6.56	9.24	4.24	3.62	0.43	2.39
Other Long-Term Assets	38.22	32.23	21.32	21.38	9.58	7.86
Total Assets	2,309	2,420	2,297	2,515	2,670	2,651
Accounts Payable	199.48	239.03	156.22	289.69	343.89	245
Accrued Expenses	145.8	142.25	133.43	150.55	148.07	125.41
Short-Term Debt	-	-	30	50	150	-
Current Portion of Long-Term Debt	-	-	-	-	-	389.88
Current Portion of Leases	8.14	9.03	7.2	8.01	6.88	5.56
Current Income Taxes Payable	14.41	24.52	46.24	36.92	40.12	70.28
Current Unearned Revenue	10.85	58.28	6.6	29.04	93.06	42.61
Other Current Liabilities	5.23	4.68	3.67	6.35	3.87	4.7
Total Current Liabilities	383.92	477.78	383.35	570.55	785.89	883.43
Long-Term Leases	103.34	113.93	116.2	122.67	127.66	118.28
Pension & Post-Retirement Benefits	-	-	-	-	-	1.87
Long-Term Deferred Tax Liabilities	6.99	3.54	0.04	3.1	2.88	1.21
Other Long-Term Liabilities	0.44	0.47	0.48	0.49	0.48	0.48
Total Liabilities	494.69	595.7	500.07	696.81	916.91	1,005
Common Stock	999.5	999.5	999.5	999.5	999.5	999.5
Additional Paid-In Capital	68.37	68.37	68.37	68.37	68.37	66.78
Retained Earnings	736.93	744.06	718.87	739.95	682.34	586.9
Treasury Stock	-	-	-	-	-	-12.25
Comprehensive Income & Other	9.3	11.67	9.69	9.51	2.52	4.45
Total Common Equity	1,814	1,824	1,796	1,817	1,753	1,645
Minority Interest	0.62	0.63	0.5	0.57	0.82	0.78
Shareholders' Equity	1,815	1,824	1,797	1,818	1,754	1,646
Total Liabilities & Equity	2,309	2,420	2,297	2,515	2,670	2,651
Total Debt	111.48	122.96	153.4	180.68	284.55	513.72
Net Cash (Debt)	449.63	475.83	290.52	216.85	340.5	309.24
Net Cash Growth	31.41%	63.79%	33.97%	-36.31%	10.11%	61.63%
Net Cash Per Share	4.48	4.74	2.90	2.15	3.22	2.74
Filing Date Shares Outstanding	99.95	99.95	99.95	99.95	99.95	99.38
Total Common Shares Outstanding	99.95	99.95	99.95	99.95	99.95	99.38
Working Capital	1,184	1,165	1,123	1,084	973.97	801.05
Book Value Per Share	18.15	18.25	17.97	18.18	17.54	16.56
Tangible Book Value	1,779	1,784	1,752	1,748	1,646	1,516
Tangible Book Value Per Share	17.80	17.85	17.53	17.49	16.47	15.26
Land	261.68	261.68	261.68	261.68	261.68	261.68
Buildings	605.02	605.02	604.13	604.13	601.96	601.58
Machinery	816.99	806.49	789.71	777.35	754.25	748.98
Leasehold Improvements	-	-	-	-	-	0.43

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.